The effect of Vitamin D supplementation on serum cardiovascular biomarkers

The effect of oral Vitamin D3 supplementation on cardiovascular risk factors in post-menopausal women in Gorgan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012091810868N1

Enrollment

120

Registered

2012-10-09

Start date

2010-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular. Antihyperlipidaemic and antiarteriosclerotic drugs

Interventions

Intervention 1: Oral pear of Vitamin D3 2000 IU daily for 12 weeks. Intervention 2: Oral pearl placebo once daily for 12 weeks.

Treatment - Drugs

Placebo

Oral pear of Vitamin D3 2000 IU daily for 12 weeks

Oral pearl placebo once daily for 12 weeks

Eligibility

Sex/Gender

Female

Age

45 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Postmenopausal women; absent of any serious diagnosed illnesses such as cardiovascular; diabetus mellitus; taking medications such as anti-diabetes; anti-hypertensive and anti-lipidemic agents; hormone replacement therapy (HRT); vitamin D and or calcium –D supplementation and smoking. Exclusion criteria: using any medication which affect the outcome variables.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HDL. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;Cholestrol. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;LDL. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;Triglyceride. Timepoint: At baseline and after 12 weeks. Method of measurement: serum.;FBS. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;Blood Pressure. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.	—

Measure

Time frame

HDL. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;Cholestrol. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;LDL. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;Triglyceride. Timepoint: At baseline and after 12 weeks. Method of measurement: serum.;FBS. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.;Blood Pressure. Timepoint: At baseline and after 12 weeks. Method of measurement: Serum.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMoghassemi Sedigheh

Golestan University of medical sciences

moghasemi.s@gmail.com+1 714430351

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026